Stock Scorecard
Stock Summary for Geron Corp (GERN) - $3.58 as of 4/17/2024 2:37:06 PM EST
Total Score
5 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GERN
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GERN
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GERN
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for GERN
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for GERN
Financial Details for GERN
Company Overview |
|
---|---|
Ticker | GERN |
Company Name | Geron Corp |
Country | USA |
Description | Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/9/2024 |
Stock Price History |
|
Last Day Price | 3.58 |
Last Day Price Updated | 4/17/2024 2:37:06 PM EST |
Last Day Volume | 6,439,992 |
Average Daily Volume | 16,999,956 |
52-Week High | 4.05 |
52-Week Low | 1.64 |
Last Price to 52 Week Low | 118.29% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 102.57 |
Sector PE | 61.99 |
5-Year Average PE | -4.48 |
Free Cash Flow Ratio | 6.28 |
Industry Free Cash Flow Ratio | 12.74 |
Sector Free Cash Flow Ratio | 30.47 |
Current Ratio Most Recent Quarter | 3.16 |
Total Cash Per Share | 0.57 |
Book Value Per Share Most Recent Quarter | 0.46 |
Price to Book Ratio | 8.64 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 9,031.79 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 588,059,000 |
Market Capitalization | 2,105,251,220 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 7.75% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -29.76% |
Reported EPS 12 Trailing Months | -0.32 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -0.33 |
Net Income Twelve Trailing Months | -184,127,000 |
Net Income Past Year | -184,127,000 |
Net Income Prior Year | -141,901,000 |
Quarterly Revenue Growth YOY | -77.70% |
5-Year Revenue Growth | -25.97% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 333,699,000 |
Total Cash Past Year | 333,699,000 |
Total Cash Prior Year | 172,746,000 |
Net Cash Position Most Recent Quarter | 238,976,000 |
Net Cash Position Past Year | 238,976,000 |
Long Term Debt Past Year | 94,723,000 |
Long Term Debt Prior Year | 60,375,000 |
Total Debt Most Recent Quarter | 94,723,000 |
Equity to Debt Ratio Past Year | 0.72 |
Equity to Debt Ratio Most Recent Quarter | 0.72 |
Total Stockholder Equity Past Year | 247,949,000 |
Total Stockholder Equity Prior Year | 79,998,000 |
Total Stockholder Equity Most Recent Quarter | 247,949,000 |
Options |
|
Put/Call Ratio | 0.04 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.28 |
MACD Signal | 0.27 |
20-Day Bollinger Lower Band | 1.25 |
20-Day Bollinger Middle Band | 2.48 |
20-Day Bollinger Upper Band | 3.71 |
Beta | 0.61 |
RSI | 68.22 |
50-Day SMA | 2.54 |
200-Day SMA | 1.98 |
System |
|
Modified | 4/16/2024 1:11:55 AM EST |